RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Sickle Cell Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Perinatal Outcome of Sickle-cell Disease in Pregnancy: A Retrospective Cross-sectional Study.
Singh Vinita et al., Annals of African medicine (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893827/
- 2.
Partial Red Cell Exchange in the Secondary Prevention of Stroke in Sickle Cell Disease: A Prospective Study.
Fethi Mellouli et al., European journal of haematology (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895074/
- 3.
Neurocognitive, School-Based, and Quality of Life Outcomes for Youth With Sickle Cell Disease and Thalassemia: A Scoping Review.
Etling Mary Ann et al., Pediatric blood & cancer (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895238/
- 4.
Macronutrient and micronutrient requirements in sickle cell disease across age groups: a narrative review.
Bhattacharjee Sarbasree et al., Journal of community genetics (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895679/
- 5.
Sickle Cell Disease in Latin America and the Caribbean: Where the Care Cascade Breaks Down
Orozco Rodríguez M et al. (19 October 2026)
https://europepmc.org/search?query=Sickle%20Cell%20Disease%20in%20Latin%20America%20and%20the%20Carib
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268 · Recruiting · Phase 3 · Novo Nordisk A/S
Ages 12 and over
https://clinicaltrials.gov/study/NCT06612268
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Sickle Cell Disease
Sickle Cell Disease is an inherited blood disorder in which red blood cells become rigid and sickle-shaped, blocking blood flow and causing severe pain, organ damage, and increased infection risk. It is most prevalent in people of African, Mediterranean, Middle Eastern, and South Asian descent. Australia has a growing population living with SCD, with newborn screening now expanding nationally.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: Sickle-cell disease (SCD) poses significant maternal and neonatal risks during pregnancy. Assessing the perinatal outcomes in pregnant women with homozygous SCD (HbSS) to optimize management strategies is the goal of this study. MATERIALS AND METHODS: A retrospective cross-sectional study was conducted at the Department of Obstetrics and Gynecology, AIIMS Raipur, Chhattisgarh, over 18 months (September 1, 2021, to February 28, 2023). All pregnant women in the third trimester with HbSS admitted to the antenatal care ward were included. Patients with chronic hypertension, diabetes, renal diseases, thalassemia syndromes, or compound sickle-cell syndromes were excluded. Data on maternal and neonatal outcomes were analyzed. RESULTS: The mean hemoglobin at admission was 7.98 + 2.19 g/dL. 65.9% of women required antenatal transfusions. 38.2% of women developed sickle-cell crisis. 23.5% of women required intensive care unit admission in the antenatal and postnatal period. Notable was the mortality of 5.8% of women, which occurred in the postnatal period. 61.8% of women underwent cesarean section, with fetal distress as the most common indication. The mean birth weight was found to be 2.51 ± 0.47 kg. However, there was no neonatal mortality. CONCLUSION: Optimizing perinatal care requires an understanding of the maternal and neonatal problems linked to SCD during pregnancy. This study emphasizes how crucial multidisciplinary management is to reducing unfavorable results.
Common Questions
What is Sickle Cell Disease?
Sickle Cell Disease is an inherited blood disorder in which red blood cells become rigid and sickle-shaped, blocking blood flow and causing severe pain, organ damage, and increased infection risk. It is most prevalent in people of African, Mediterranean, Middle Eastern, and South Asian descent. Australia has a growing population living with SCD, with newborn screening now expanding nationally.
How many clinical trials are available for Sickle Cell Disease?
RareWays currently indexes 778 clinical trials for Sickle Cell Disease, of which 112 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Sickle Cell Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Sickle Cell Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.